Leela Barham and Tim Wilsdon discuss the potential impact that value-based pricing (VBP) may have in the UK and the broader implications for developing international models of Health Technology Assessment (HTA). The article can be found here:
CRA presents at AXS25 "GLP-1s: Riding the Wave of Innovative Medications"
Read the key takeaways here.